A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa

Area of Science:

• Microbiology
• Biotechnology
• Antimicrobial Research

Background:

• Rising global incidence of multidrug-resistant (MDR) bacteria necessitates novel therapeutic strategies.
• Phage therapy is regaining attention as a potential solution to combat MDR infections.

Purpose of the Study:

• To evaluate the efficacy of a novel endolysin, LysPA26, against multidrug-resistant Pseudomonas aeruginosa.
• To assess the stability and spectrum of activity of LysPA26 against Gram-negative pathogens.

Main Methods:

• Screening of LysPA26 against MDR P. aeruginosa.
• Assessing LysPA26 activity without outer-membrane permeabilization.
• Conducting temperature and pH stability assays.
• Testing LysPA26 against various Gram-negative and Gram-positive bacteria.
• Evaluating LysPA26's efficacy in eliminating P. aeruginosa biofilms.

Main Results:

• LysPA26 demonstrated potent activity against MDR P. aeruginosa, achieving up to 4 log unit reduction in 30 minutes.
• The endolysin exhibited stability across a wide range of temperatures and pH levels.
• LysPA26 effectively killed P. aeruginosa in biofilm formation.
• Activity was observed against other Gram-negative bacteria (Klebsiella pneumonia, Acinetobacter baumannii, Escherichia coli) but not Gram-positive bacteria.

Conclusions:

• LysPA26 is a novel and effective antimicrobial agent against Gram-negative pathogens.
• Its stability and efficacy against biofilms make it a promising candidate for combating MDR infections.
• LysPA26 represents a potential new therapeutic approach in the fight against resistant bacterial infections.